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Nano-MoO3-mediated synthesis of bioactive
thiazolidin-4-ones acting as anti-bacterial agents
and their mode-of-action analysis using in silico
target prediction, docking and similarity searching†
Keerthy Hosadurga Kumar,a Shardul Paricharak,bc Chakrabhavi Dhananjaya Mohan,d
Hanumantharayappa Bharathkumar,a G. P. Nagabhushana,e Dinesh Koragere Rajashekar,a
Gujjarahalli Thimmanna Chandrappa,e Andreas Bender,*b Basappa*a and
Kanchugarakoppal Subbegowda Rangappa*d
The eﬃcacy of thiazolidin-4-ones as synthons for diverse biological small molecules has given impetus to
anti-bacterial studies. Our work aims to synthesize novel bioactive thiazolidin-4-ones using nano-MoO3 for
the first time. The compelling advantage of using nano-MoO3 is that the recovered nano-MoO3 can be
reused thrice without considerable loss of its catalytic activity. The synthesized thiazolidin-4-ones were tested
for anti-bacterial activity against two strains of pathogenic bacteria, namely, Salmonella typhi and Klebsiella
pneumoniae. Our results indicated that 3-(benzo[d]isoxazol-3-yl)-2-(3-methoxyphenyl)thiazolidine-4-one
(compound 3b) showed significant inhibitory activity towards Salmonella typhi, in comparison with gentamicin.
Furthermore, in silico target prediction presented the target of compound 3b as the FtsK motor domain of
DNA translocase of Salmonella typhi. Hence, our hypothesis is that compound 3b may disrupt chromosomal
segregation and thereby inhibit the division of Salmonella typhi. In addition, similarity searching showed that
34 compounds with a chemical similarity of 70% or higher to compound 3b, which were retrieved from
ChEMBL, bound to targets associated with biological processes related to cell development in 36% of the
cases. In summary, our work details novel usage of nano-MoO3 for the synthesis of novel thiazolidin-4-ones
possessing anti-bacterial activity, and presents a mode-of-action hypothesis.
1. Introduction
Transition metal oxides are extensively used in many organic
reactions owing to advantages over their counterparts.1 The use
of coordination compounds with a variety of metals has
replaced acids or bases, with satisfactory yields. Use of acid
or bases often results in low product yield due to reverse/side
reactions and the use of organic solvents increases the diﬃculty
in catalyst recovery.2 Molybdenum oxide (MoO3) is projected as
a potential nanostructure because of its wide range of stoichio-
metric, structural, thermal, chemical and optical properties.3–5
MoO2- or MoO3-supported catalysts are reported to efficiently
catalyze various organic reactions including the Beckmann
rearrangement,6 nitration of aromatics,7 oxidation of ammonia
to elemental N2 and synthesis of diphenyl carbonate from
dimethyl carbonate and phenol.8 In the present work, we report
the use of MoO3 for the synthesis of novel thiazolidin-4-ones
and analyze the anti-bacterial activity of new structures.
Antibiotic resistance is a major concern in contemporary
medicine and has emerged as one of the prominent public
health issues of the 21st century,9 particularly as it pertains to
pathogenic organisms such as Salmonella typhi and Klebsiella
pneumoniae.10 S. typhi and K. pneumoniae are pathogenic Gram-
negative bacterial strains; the former is found predominantly in
the intestinal lumen and the latter in the gastrointestinal tract
and naso-pharynx.
Diverse species of pathogenic Gram-negative bacteria use
secretion systems to export a variety of protein toxins and
virulence factors that help to establish and maintain infection.
Disruption of such secretion systems is a potentially eﬀective
therapeutic strategy against these bacterial infections. In order
to develop small-molecule anti-bacterials, we subjected the title
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compounds to a high-throughput screen and identified a tris-aryl
substituted 2-imino-5-arylidenethiazolidin-4-one, compound 3b, as
an inhibitor of the Type III secretion system. Expansion of this
chemotype enabled us to define the essential pharmacophore for
Type III secretion inhibition by this structural class.11,12
In a continuation of our work to synthesize and explore the
pharmacological properties of various classes of heterocycles,13–20 we
report here the application of MoO3 nanoparticles in the
synthesis of novel thizolidin-4-ones, followed by their use as
anti-bacterial agents against S. typhi and K. pneumoniae.
Furthermore, we used chemogenomics approaches to predict
protein targets in silico and rationalized the mode of action of
the bioactive thiazolidin-4-one.
2. Results and discussion
2.1 Characterization of nano-MoO3
The powder XRD pattern was recorded on a PANalytical X’pert
PRO X-ray diﬀractometer with a graphite monochromatized Cu
Ka radiation source (l = 1.541 Å). Morphologies and particle
sizes of combustion-derived powders were examined using a
JEOL-JSM-6490 LV scanning electron microscope (SEM) and a
transmission electron microscope (TEM) by JEOL JEM 2100
operating at 200 kV.
The powder XRD patterns, SEM image and TEM image of
nano-MoO3 are shown in Fig. 1a–c and are reported elsewhere.
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2.2 Selection of reaction system and optimization of reaction
conditions
Initially, we synthesized thiazolidin-4-ones by the reaction of
p-anisaldehyde (1a) with b-naphthyl amine (2a) using various
methodologies as reported in Table 1 and came up with a
stabilized protocol using MoO3.
We found that the use of nano-MoO3 in ethanol is the ideal
system for the ring-forming condensation reaction. The reactions
with other methodologies resulted in low yields, while nano-MoO3
in refluxing ethanol led to comparatively high yields of the product.
2.3 Ethanol as the ideal reaction media and reusability of the
acidic nano-MoO3
To achieve a stabilized reaction system for thiazolidin-4-ones
synthesis, we considered the reaction between p-anisaldehyde
(1 eq.) (1a) and b-naphthyl amine (1 eq.) (2a) (Scheme 1a). The
reaction between 1a and 2a in the presence of nano-MoO3
(1 eq.) in ethanol at 70 1C resulted in a product (3a) yield of 52%
after 6.2 h (Table 2, entry 1). An increase in the amount of nano-
MoO3 (1.8 eq.) resulted in an increase in product yield to 94%
within 4 h (Table 2, entries 2 and 3). Further increase in the
amount of nano-MoO3 in the reaction does not aﬀect the
reaction time and yield (Table 2, entry 4). The presence of
vacant d-orbital molybdenum oxide facilitates the formation of
arylimine intermediate between 1a and 2a, and its acidic nature
facilitates the process of cyclization of arylimine and thioglycolic
acid, forming the product 3a.
Subsequently, we attempted to explore a better solvent system
for the reaction with various polar and non-polar solvents. The
reaction was monitored in solvents such as acetonitrile :water,
ethanol :water, n-butanol, THF, benzene and toluene. All the
tested solvent systems displayed an inferior product yield (3a) to
that of ethanol (Table 2, entries 1–10).
We next analyzed the reusability of nano-MoO3, which was
used in the synthesis of thiazolidin-4-one as represented in
Scheme 1a. Each time after the completion of the reaction,
filtered residue containing nano-MoO3 was washed with ethanol
and reused for the next run with fresh p-anisaldehyde, 2-naphthyl
amine and thioglycolic acid. We observed a considerable decrease
in product yield on reusing nano-MoO3 after the third run.
The second and third runs resulted in yields of 74% and 65%,
respectively.
We finally used the optimized reaction conditions to prepare
the novel series of thiazolidin-4-ones, in which we used aryl/
heteroaryl aldehydes with heteroaryl amines and thioglycolic
acid (Scheme 1b). Most of the aldehydes and amines bearing
various electron-donating and electron-withdrawing substituents
resulted in products with high yields (Table 2 entries 2–15).
2.4 Anti-bacterial activity
The minimum inhibitory concentration (MIC) of the com-
pound, which is required for inhibition of bacterial growth by
the compounds 3(a–o), along with the MIC of a reference drug
(gentamicin), are shown in Table 4. Of the benzisoxazole and
indole series, compounds 3b and 3c (benzisoxazole series) and
compound 3l (indole series) showed significant anti-bacterial
activity towards S. typhii, with zone of inhibition values of
23 mm, 17 mm and 16 mm, respectively, and MIC values of
Fig. 1 (a) Powder XRD patterns of MoO3 powders. (b) SEM image of
MoO3. (c) TEM image of MoO3. The detailed characterization was reported
previously.21
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300 mgml1, 400 mgml1 and 800 mgml1, respectively. Compounds
3e and 3l were found to be effective against K. pneumoniaei, with
zone of inhibition values of 14 mm and 14 mm, respectively, and
MIC values of 700 mg ml1 and 400 mg ml1, respectively.
2.5 Cheminformatics
Human protein targets were predicted for the most bioactive
compound 3b, which was shown to have an inhibitory eﬀect on
the growth of S. typhi.23 The predicted target, potassium
voltage-gated channel subfamily A member 5, with a corre-
sponding probability value of 0.069, is shown in Table 5. In
addition, the occurrence of potassium voltage-gated channel
subfamily A member 5 in the background dataset was measured.
It was found that the potassium voltage-gated channel subfamily A
member 5 had a normalized likelihood of 5882 for compound 3b,
meaning that this prediction is very unlikely to have occurred by
chance alone. Given that the predicted protein, potassium
voltage-gated channel subfamily A member 5, is a human
protein, a DELTA-BLAST search was performed on the pre-
dicted target protein in order to find orthologous proteins in
S. typhi (results shown in Table 6). We found that the predicted
target, potassium voltage-gated channel subfamily A member 5,
had sequence homology to the following S. typhi proteins: putative
surface-exposed virulence protein BigA (Uniprot ID: P25927.2),
proline-specific permease ProY (Uniprot ID: P37460.3) and DNA
translocase FtsK (Uniprot ID: Q8ZQD5.1), with e-values of 3 106,
3  104 and 0.002, respectively. Given that the putative surface-
exposed virulence protein BigA (Uniprot ID: P25927.2) is involved in
virulence of bacteria and that the proline-specific permease ProY
(Uniprot ID: P37460.3) is the structural gene for a cryptic proline
transporter,24,25 we hypothesize the DNA translocase FtsK (Uniprot
ID: Q8ZQD5.1) to be the target responsible for growth inhibition of
S. typhi.
In addition, in order to investigate the bioactivity profile of
compounds similar to compound 3b and thus to understand
the target prediction of compound 3b from the chemical
perspective, bioactivity data were retrieved for 34 compounds
from ChEMBL with a similarity of 70% or higher to compound
3b, covering 39 unique protein targets. Of these, 32 targets had
a PANTHER26 ‘‘biological process’’ annotation. It can be seen
that in 36% of the cases, the proteins are associated with the
terms ‘‘cellular process’’, ‘‘cell communication’’, ‘‘cell cycle’’,
‘‘cellular component organization’’ or ‘‘apoptosis’’. These
results indicate that compounds similar to compound 3b could
very well be involved in the disruption of cellular development
and hence are in agreement with our prediction that DNA
translocase FtsK is the mode of action for compound 3b, given
that DNA translocase FtsK is also of importance in cellular
development.27,28
2.6 Rationalization of putative target of the bioactive
thiazolidin-4-ones via in silico molecular docking
Given that our cheminformatics approaches present the predicted
putative target, namely the DNA translocase FtsK, as a mode-of-
action hypothesis, we subsequently performed molecular docking
studies to understand the ligand–protein interactions in detail.
FtsK is a conserved DNA translocase, whose action is crucial in
bacterial cell division during the late stages of chromosome
segregation.18,19,29,30 In addition, deletion or over-expression of
FtsK can result in the inhibition of cell division.20 The docking
scores (DS) of the docked compounds with the FtsK motor domain
are summarized in Table 7. The thiazolidin-4-one derivatives show
DS scores higher than 50, and are therefore likely to interact
with the FtsK motor domain based on this model (Table 4).
Table 2 Nano-MoO3 catalyzed synthesis of compound 3a under diﬀerent
reaction conditions
Entry Solvent
Nano MoO3
(eq.)
Time
(h)
Temperature
(1C)
Yielda
(%)
1 Ethanol 1.0 6.2 70 52
2 Ethanol 1.5 6 70 70
3 Ethanol 1.8 4 70 94
4 Acetonitrile : water (8 : 2) 1.8 10 75 Traces
5 Ethanol : water (8 : 2) 1.8 12 80 Traces
6 n-Butanol 1.8 9 110 78
7 THF 1.8 8.5 65 72
8 Benzene 1.8 42 80 63
9 Toluene 1.8 36 110 58
10 Acetonitrile 1.8 7.5 70 82
a Yield of product after column chromatography.
Table 1 Comparative study of diﬀerent methods and solvents for thiazolidin-4-one formation
Sl. no. Method Solvent Temperature (1C) Amount of reagent (eq.) Yielda (%) Time (h)
1 ZnCl2 Ethanol 80 2 71 32
2 Dean–Stark’s Toluene 110 — 78 48
3 DCC THF 0–25 2.5 67 2.5
4 T3P Ethyl acetate : DMSO 0–25 2.5 82 6
5 Nano-MoO3 Ethanol 70 1.8 94 4
a DCC = N,N0-dicyclohexylcarbodiimide, THF = tetrahydrofuran, T3P = propylphosphonic anhydride.
Scheme 1 (a) Synthesis of 2-(4-methoxyphenyl)-3-(naphthalen-1-
yl)thiazolidin-4-one.22 (b) Synthesis of novel series of thiazolidin-4-ones
3(b–o).
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Table 3 Novel thiazolidin-4-ones synthesized using nano-MoO3
Entrya Aldehyde (1) Amine (2) 3(b–o) Time (h) Yieldb (%)
1 3 96
2 2.5 90
3 2.5 93
4 3 91
5 3.5 89
6 4 90
7 3 92
8 5 86
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Furthermore, compounds 3b and 3l (both in S-form) from the
benzisoxazole and the indole series were shown to be likely to
interact with the hydrophilic pocket of the FtsK motor domain,
with a high DS of 64.6 and 50.4, respectively. Fig. 2 and 3
present comparative interaction maps of compounds 3b and 3l,
respectively, with the hydrophobic site of the FtsK motor domain.
The interaction between both compounds and FtsK can be viewed
in terms of their binding to three clusters of the FtsK motor
domain. The amino acids Lys1183, Arg1187, Asn908, Ala904 and
Ser907 of the FtsK motor domain are predicted to interact with the
benzisoxazole or indole rings, whereas the amino acids Glu1196,
Gly1194, Gln1192, Ala1193, and Val924 appear to interact with the
thiazolidin-4-one nucleus. The third cluster consists of the amino
acids Pro1214, Arg1216, Leu1213, Val1215, Glu926, Val925, Val927
Table 3 (continued )
Entrya Aldehyde (1) Amine (2) 3(b–o) Time (h) Yieldb (%)
9 3.5 92
10 3 93
11 4.5 88
12 4 90
13 3 92
14 3.5 91
a Conditions: aldehyde : amine : thioglycolic acid: nano-MoO3 = 1 : 1 : 1.5 : 1.8 (eq.).
b Isolated yield after column chromatography.
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and Pro929 that are buried by the substituted phenyl or substituted-
imidazole moiety. In addition to the fact that both compounds 3b
and 3l were predicted to interact with the FtsK motor domain, both
efficiently inhibited bacterial growth. Therefore, the potent inhibi-
tion by compound 3b of S. typhi growth might be due to the strong
and unique hydrogen bonding between the amino acids Lys1183
and Arg1187 and benzisoxazole heteroatoms and also between the
amino acid Arg923 and the methoxy-phenyl group of compound 3b.
In short, the interactions predicted between compound 3b and the
FtsK motor domain are representative of other putative inhibitors in
the same domain.
2.7 Conclusions
In this study, we have developed a synthetic method for novel
bioactive thiazolidine-4-ones by condensation of aryl/heteroaryl
aldehydes and heteroaryl amines using nano-MoO3 for the first
time. The anti-bacterial activity of the synthesized thiazolidin-4-ones
against two pathogenic strains, namely S. typhi and K. pneumoniae,
revealed that compound 3b showed significant inhibitory activity
towards S. typhi, with an activity comparable to gentamicin. Further-
more, in silico human target prediction for compound 3b predicted
the FtsK domain of DNA translocase as a putative target. In addition,
our molecular docking analysis suggests that the highly active
compound 3b strongly interacts with the FtsK motor domain, when
compared to other structurally related compounds, thereby indicat-
ing that it may disrupt chromosome segregation and thus inhibit
cell division of S. typhi in culture.
3. Experimental section
3.1 Synthesis of nano-MoO3
Nano-MoO3 was synthesized according to a reported procedure.
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3.2 Synthesis of novel thiazolidin-4-ones
All reagents were of commercially available reagent grade and were
used without further purification. Thin layer chromatography (TLC)
was conducted on 0.25 mm silica gel plates (60F254, Merck).
Column chromatography separations were obtained on silica
gel (200–400 mesh). IR spectra were recorded on a Bruker FTIR
spectrophotometer. 1H NMR spectra were recorded on a Bruker
Avance-400 instrument (together with a small number on an
Agilent NMR instrument) in DMSO-d6 (and a small number in
CDCl3) solvent.
13C NMR spectra were obtained on an Agilent
NMR instrument at 100 MHz in DMSO-d6 solvent (and a small
number in CDCl3). Chemical shifts were expressed in ppm
downfield relative to the TMS. Mass spectra were recorded on
an Agilent LC-MS. The elemental analysis was carried out using
an Elemental Vario Micro Cube CHN analyzer.
3.3 General procedure
Aryl/heteroaryl aldehyde (1 eq.), heteroaryl amine (1 eq.) and
thioglycolic acid (1.5 eq.) were refluxed in ethanol in the presence of
nano-MoO3 (1.8 eq.) for the stipulated time (Table 3). The reaction
wasmonitored for completion by thin-layer chromatography using a
hexane :ethylacetate (7 :3) mobile phase. After completion of the
reaction, the reaction mixture was brought to room temperature,
filtered through Whatman filter paper 42 and the solvent was
removed under vacuum to obtain the novel thiazolidin-4-ones
(3a–o). The pure product was obtained by column chromatography
using ethyl acetate and n-hexane (85 ml), and ethyl acetate (15 ml)
as eluent.
Table 4 Anti-bacterial activities: zone of inhibition for thiazolidin-4-ones
3(b–o) towards S. typhi and K. pneumoniae
Compounds
Klebsiella pneumoniae
(zone of inhibition
in mm)
Salmonella typhi
(zone of inhibition
in mm)
3b 14 23
3c 14 17
3d NAa NAa
3e 12 NAa
3f 14 11
3g NA NA
3h 16 12
3i 12 16
3j 14 24
3k NAa NAa
3l 14 16
3m 12 11
3n 14 15
3o 18 13
Gentamicin 32 35
a NA = not active.
Table 5 In silico human target predictions listed for thiazolidin-4-ones using Parzen–Rosenblatt Window classifier
Compound Predicted target 1 (PRW)
Uniprot
ID Probability Predicted target 1 (NB)
Uniprot
ID Probability
3b Potassium voltage-gated channel
subfamily A member 5
P22460 0.069 Endothelin B receptor P24530 6.60
3c Sigma non-opioid intracellular receptor 1 Q99720 0.052 Receptor-type tyrosine-protein kinase FLT3 P36888 5.82
3d Sigma non-opioid intracellular receptor 1 Q99720 0.053 Receptor-type tyrosine-protein kinase FLT3 P36888 5.92
3e Sigma non-opioid intracellular receptor 1 Q99720 0.06 Receptor-type tyrosine-protein kinase FLT3 P36888 7.42
3f Prostaglandin G/H synthase 2 P23219 0.05 Potassium voltage-gated channel
subfamily A member 5
P22460 5.55
3g Sigma non-opioid intracellular receptor 1 Q99720 0.079 1-Acyl-sn-glycerol-3-phosphate acyltransferase
beta
O15120 10.33
3i Carbonic anhydrase 2 P00918 0.083 Type-2 angiotensin II receptor P50052 9.59
3j Prostaglandin G/H synthase P23219 0.112 TGF-beta receptor type-1 P36897 7.61
3k Prostaglandin G/H synthase P23219 0.1 Tyrosine-protein kinase ITK/TSK Q08881 7.38
3l Carbonic anhydrase 2 P00918 0.061 Type-1 angiotensin II receptor 21.59
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3.4 Spectral characterization of novel thiazolidine-4-ones 3(b–o)
3-(Benzo[d]isoxazol-3-yl)-2-(3-methoxyphenyl)thiazolidine-4-
one (3b). IR (KBr): 1728 cm1 n(CQO);
1H NMR (400 MHz, DMSO
d6 d in ppm) d 8.002 (s, 1H, Ar-H), 7.664–7.639 (m, 2H, Ar-H),
7.419–7.396 (m, 1H, Ar-H), 7.177–7.157 (m, 1H, Ar-H), 7.005–
6.984 (m, 2H, Ar-H), 6.797–6.774 (m, 1H, Ar-H), 6.561 (s, 1H,
S–CH–), 4.199–4.196 (d, J = 1.2 Hz, 1H, –CH2–), 4.159–4.156
(d, J = 1.2 Hz, 1H, –CH2–), 3.644 (s, 3H, –OCH3);
13C NMR
(100 MHz, CDCl3 d in ppm) d 173.21, 163.19, 159.21, 148.11,
139.28, 130.54, 128.52, 123.91, 122.52, 120.55, 111.21, 108.57,
67.33, 55.11, 32.12; ESI-MS m/z 327 [M + H]+; anal. calcd for
C17H14N2O3S: C, 62.56; H, 4.32; N, 8.58; found C, 62.49; H, 4.26;
N, 8.45%.
3-(Benzo[d]isoxazol-3-yl)-2-(4-nitrophenyl)thiazolidine-4-one
(3c). IR (KBr): 1716 cm1 n(CQO); 1H NMR (400 MHz, DMSO d6 d
in ppm) d 1H NMR (400 MHz, DMSO d6 d in ppm) d 8.156–8.073
(m, 2H, Ar-H), 7.769–7.747 (m, 2H, Ar-H), 7.667–7.650 (m, 2H,
Ar-H), 7.432–7.407 (m, 2H, Ar-H), 6.743 (s, 1H, S–CH–), 4.244–
4.242 (d, J = 0.8 Hz, 1H, –CH2–), 4.204–4.202 (d, J = 0.8 Hz, 1H,
–CH2–);
13C NMR (100 MHz, DMSO-d6 d in ppm) d 171.52,
162.51, 147.11, 146.28, 144.21, 130.74, 129.42, 123.01, 122.45,
119.42, 108.56, 74.27, 32.61; ESI-MS m/z 342 [M + H]+; anal.
calcd for C16H11N3O4S: C, 56.30; H, 3.25; N, 12.31: found: C,
56.19; H, 3.18; N, 12.09%.
3-(Benzo[d]isoxazol-3-yl)-2-(2-nitrophenyl)thiazolidine-4-one
(3d). IR (KBr): 1717 cm1 n(CQO):
1H NMR (400 MHz, DMSO d6 d
in ppm) d 8.168–8.086 (m, 2H, Ar-H), 7.716–7.694 (m, 2H, Ar-H),
7.674–7.672 (m, 2H, Ar-H), 7.666–7.421 (m, 2H, Ar-H), 6.862
(s, 1H, S–CH–), 4.207–4.204 (d, J = 1.2 Hz, 1H, –CH2–), 4.166–4.163
(d, J = 1.2 Hz, 1H, –CH2–);
13C NMR (100 MHz, DMSO-d6 d in ppm)
d 170.34, 164.21, 149.05, 147.68, 135.01, 134.12, 130.98, 128.86,
127.20, 125.06, 123.67, 122.76, 108.51, 67.98, 33.81; ESI-MS m/z
342 [M + H]+; anal. calcd for C16H11N3O4S: C, 56.30; H, 3.25; N,
12.31; found C, 56.22; H, 3.19; N, 12.24%.
3-(Benzo[d]isoxazol-3-yl)-2-(3-nitrophenyl)thiazolidine-4-one
(3e). IR (KBr): 1713 cm1 n(CQO):
1H NMR (400 MHz, DMSO d6 d
in ppm) d 8.0 (s, 1H, Ar-H), 7.7–7.6 (m, 2H, Ar-H), 7.4 (m, 1H,
Ar-H), 7.2–7.1 (m, 1H, Ar-H), 7.0–6.9 (m, 2H, Ar-H), 6.8 (m, 1H,
Ar-H), 6.5 (s, 1H, S–CH–), 4.2 (d, 1H, –CH2–), 4.1 (d, 1H, –CH2–);
13C NMR (100 MHz, DMSO-d6 d in ppm) d 170.23, 164.12,
147.21, 146.91, 140.86, 133.64, 130.12, 129.04, 124.85, 123.28,
122.6, 121.52, 108.62, 72.53, 34.01; ESI-MS m/z 342 [M + H]+;
anal. calcd for C16H11N3O4S requires C, 56.30; H, 3.25; N, 12.31:
found C, 56.26; H, 3.13; N, 12.25%.
3-(Benzo[d]isoxazol-3-yl)-2-(4-fluorophenyl)thiazolidine-4-one
(3f). IR (KBr): 1720 cm1 n(CQO): 1H NMR (400 MHz, DMSO d6 d
in ppm) d 7.977 (s, 1H, Ar-H), 7.655–7.636 (m, 2H, Ar-H),
7.544–7.509 (m, 2H, Ar-H), 7.410–7.075 (m, 2H, Ar-H), 6.597
(s, 1H, S–CH–), 4.206–4.204 (d, J = 0.8 Hz, 1H, –CH2–), 4.166–
4.164 (d, J = 0.8 Hz, 1H, –CH2–);
13C NMR (100 MHz, DMSO-d6 d
in ppm) d 170.15, 165.11, 159.25, 145.12, 134.24, 130.28, 123.55,
122.91, 121.46, 116.38, 115.12, 108.21, 72.21, 34.15; ESI-MS m/z
315 [M + H]+; anal. calcd for C16H11FN2O2S: C, 61.14; H, 3.53; N,
8.91; found: C, 61.05; H, 3.42; N, 8.87%.
3-(5-Bromobenzo[d]isoxazol-3yl)-2-(3-nitrophenyl)thiazolidine-
4-one (3g). IR (KBr): 1719 cm1 n(CQO):
1H NMR (400 MHz, DMSO
Table 6 DELTA-BLAST results for potassium voltage-gated channel subfamily A member 5
# blastp
# Iteration: 1
# Query: gi|146345443|sp|P22460.4|KCNA5_HUMAN Potassium voltage-gated channel subfamily A member 5
# Database: swissprot
Hit ID % Identity % Positives
Alignment
length Mismatches
Gap
opens q. start q. end s. start s. end e-value Bit score
Putative surface-exposed
virulence protein BigA
14.29 24.76 105 89 1 5 109 107 210 3.00  106 46.2
Putative surface-exposed
virulence protein BigA
12.96 24.07 108 88 2 5 106 116 223 5.00  105 42.4
Putative surface-exposed
virulence protein BigA
15.45 27.27 110 85 2 5 106 125 234 8.00  105 41.6
Putative surface-exposed
virulence protein BigA
15.53 24.27 103 80 2 6 106 82 179 0.002 37
Putative surface-exposed
virulence protein BigA
12.5 21.59 88 74 1 32 116 94 181 0.003 36.6
Putative surface-exposed
virulence protein BigA
11.24 17.98 89 72 2 28 109 78 166 0.033 33.1
Proline-specific permease
ProY
10.71 37.5 112 89 2 421 527 320 425 3.00  104 39.3
DNA translocase FtsK 11.49 18.39 87 72 2 18 99 393 479 0.002 37.4
DNA translocase FtsK 17.89 26.32 95 73 2 16 105 401 495 0.01 34.7
Table 7 Predicted binding energies of thiazolidin-4-ones with FtsK DNA
translocasea
Compounds MW PLP1 PLP2 DS LIE
3b 326.37 80.82 78.77 64.622 1.458
3j 353.39 76.9 65.06 47.504 2.452
3k 387.29 75.39 65.47 47.539 2.246
3l 388.91 70.78 60.03 50.354 6.210
3i 455.67 53.45 46.78 52.749 7.170
a MW = molecular weight, PLP1 = piecewise linear potential1, PLP2 =
piecewise linear potential2, LIE = ligand internal energy, DS = docking
score.
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d6 d in ppm) d 8.0–6.7 (m, 7H, Ar-H), 6.5 (s, 1H, S–CH–), 4.2
(d, 1H, –CH2–), 4.1 (d, 1H, –CH2–);
13C NMR (100 MHz, DMSO-d6
d in ppm) d 170.21, 163.71, 148.12, 145.28, 139.71, 134.18, 132.12,
128.12, 125.31, 124.11, 119.37, 115.11, 112.55, 65.17, 35.28;
ESI-MS m/z 419 [M + H]+; anal. calcd for C16H10BrN3O4S: C,
45.73; H, 2.40; N, 10.00; found C, 45.59; H, 2.31; N, 9.83%.
3-(5-Bromobenzo[d]isoxazol-3-yl)-2-(4-bromophenyl)thiazoli-
dine-4-one (3h). IR (KBr): 1715 cm1 n(CQO): 1H NMR (400 MHz,
CDCl3 d in ppm) d 7.821–7.757 (m, 4H, Ar-H), 7.564 (s, 1H, Ar-H),
7.321–7.201 (m, 1H, Ar-H), 6.434 (s, 1H, –S–CH–), 4.202–4.196
(d, J = 2.4 Hz, 1H, –CH2–), 4.120–4.114 (d, J = 2.4 Hz, 1H, –CH2–);
13C NMR (100 MHz, CDCl3 d in ppm) d 171.03, 164.61, 148.20,
138.66, 134.36, 131.92, 130.67, 128.06, 123.06, 121.96, 118.24,
112.28, 73.29, 33.93; ESI-MS m/z 455 [M + H]+; anal. calcd for
C16H10N2O2BrS: C, 42.32; H, 2.22; N, 6.17: found: C, 42.25; H,
2.16; N, 6.11%.
3-(5-Bromobenzo[d]isoxazol-3yl)-2-(2-butyl-4-chloro-1H-imidazol-
5-yl)thiazolidine-4-one (3i). IR (KBr): 1733 cm1 n(CQO):
1H NMR
(400 MHz, DMSO d6 d in ppm) d 9.9 (s, 1H, –NH–), 7.6 (m, 2H,
Ar-H), 7.4 (m, 1H, Ar-H), 6.7 (s, 1H, S–CH–), 4.2 (d, 1H, –CH2–), 4.0
(d, 1H, –CH2–), 2.5 (t, 2H, –CH2–), 1.4 (m, 2H, –CH2–), 1.2 (m, 2H,
–CH2–), 0.9 (m, 3H, –CH3);
13C NMR (100MHz, DMSO-d6 d in ppm)
d 170.89, 164.25, 148.31, 147.46, 135.29, 127.98, 124.06, 122.68,
118.44, 112.15, 58.79, 34.18, 30.97, 28.54, 22.65, 13.85; ESI-MS m/z
456 [M + H]+; anal. calcd for C17H16BrClN4O2S: C, 44.80; H, 3.54; N,
12.29; found C, 44.71; H, 3.49; N, 12.22%.
3-(2-Methyl-1H-indol-5-yl)-2-(3-nitrophenyl)thiazolidine-4-one
(3j). IR (KBr): 1720 cm1 n(CQO):
1H NMR (400 MHz, DMSO d6 d
in ppm) d 10.928 (s, 1H, –NH–), 8.203 (s, 1H, Ar-H), 8.126 (m, 1H,
Ar-H), 7.907 (m, 1H, Ar-H), 7.573 (m, 1H, Ar-H), 7.255 (s, 1H,
Ar-H), 7.141–7.120 (m, 1H, Ar-H), 6.864–6.838 (m, 1H, Ar-H),
6.599 (s, 1H, S–CH–), 6.028 (m, 8H, Ar-H), 4.106–4.102 (d, J =
1.6 Hz, 1H, –CH2–), 4.067–4.063 (d, J = 1.6 Hz, 1H, –CH2–), 2.169
(s, 3H, –CH3–);
13C NMR (100 MHz, DMSO-d6 d in ppm) d 169.25,
148.41, 139.66, 134.97, 133.67, 130.29, 128.31, 124.53, 120.12,
112.92, 108.52, 100.91, 73.49, 35.31, 15.86; ESI-MS m/z 354
[M + H]+; anal. calcd for C18H15N3O3S requires: C, 61.18;
H,4.28 N, 11.89; found: C, 61.11; H, 4.20; N, 11.15%.
2-(4-Bromophenyl)-3-(2-methyl-1H-indol-5-yl)thiazolidine-4-one
(3k). IR (KBr): 1722 cm1 n(CQO): 1H NMR (400MHz, DMSO d6 d in
ppm) 10.7 (s, 1H, –NH–), 7.5 (m, 2H, Ar-H), 7.4 (s, 1H, Ar-H),
7.1 (m, 2H, Ar-H), 6.9 (m, 2H, Ar-H), 6.6 (s, 1H, S–CH–), 6.0 (s, 1H,
–NCH–), 4.1 (d, 1H, –CH2–), 4.0 (d, 1H, –CH2–), 2.3 (s, 3H, –CH3);
13C NMR (100 MHz, CDCl3 d in ppm) d 171.51, 139.36, 135.86,
134.59, 132.71, 131.22, 130.34, 128.72, 121.99, 112.86, 111.68,
108.92, 102.34, 73.28, 33.84, 13.96; ESI-MS m/z 388 [M + H]+; anal.
calcd for C18H15BrN2OS C, 55.85; H,3.90; N, 7.23; found C, 55.69;
H, 3.85; N, 7.13%.
2-(2-Butyl-4-chloro-1H-imidazol-5-yl)-3-(2-methyl-1H-indol-5-
yl)thiazolidine-4-one (3l). IR (KBr): 1689 cm1 n(CQO):
1H NMR
(400 MHz, DMSO d6 d in ppm) d 7.7 (s, 1H, Ar-H), 7.2 (s, 1H,
Ar-H), 7.0 (s, 1H, Ar-H), 6.1 (s, 1H, S–CH–), 4.2 (d, 1H, –CH2–),
4.0 (d, 1H, –CH2–), 2.9 (t, 2H, –CH2–), 2.4 (s, 2H, –NH–), 2.2
(s, 3H, –CH3), 1.4 (m, 2H, –CH2–), 1.2 (m, 2H, –CH2–), 0.9 (t, 3H,
–CH3);
13C NMR (100 MHz, DMSO-d6 d in ppm) d 172.35,
148.05, 134.39, 133.25, 131.57, 128.20, 124.19, 113.57, 108.53,
102.61, 57.91, 34.97, 31.11, 28.52, 22.72, 15.89, 13.28; ESI-MS
m/z 389 [M + H]+; anal. calcd for C19H21ClN4OS C, 58.68; H,
5.44; N, 14.41; found: C, 58.55; H, 5.25; N, 14.29%.
3-(1-Oxo-1,3-dihydroisobenzofuran-5-yl)-2-(2,4,6-trifluorophenyl)-
thiazolidine-4-one (3m). IR (KBr): 1721 cm1 n(CQO):
1H NMR
(400 MHz, DMSO d6 d in ppm) d 8.230–8.218 (d, 1H, Ar-H),
7.846–7.825 (d, 1H, Ar-H), 7.237 (s, 1H, Ar-H), 6.518 (s, 1H, S–CH–),
6.326–6.267 (m, 2H, Ar-H), 5.381 (s, 2H, –COCH2–), 4.411–4.403
(s, J = 3.2 Hz, 2H, –CH2–), 4.320–4.312 (d, J = 3.2 Hz, 1H, –CH2–);
Fig. 2 Interaction map showing key amino acids of the FtsK motor
domain of S. typhi bound to compound 3b.
Fig. 3 Interaction map showing key amino acids of the FtsK motor
domain of S. typhi bound to compound 3l.
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13C NMR (100 MHz, DMSO-d6 d in ppm) d 171.94, 163.87, 146.01,
144.40, 130.39, 124.72, 121.62, 118.82, 107.45, 100.58, 70.01, 55.42,
35.58; ESI-MS m/z 366 [M + H]+; anal. calcd for C17H10NO3F3S: C,
55.89; H, 2.76; N, 3.83: found: C, 55.78; H, 2.68; N, 3.75%.
2-(4-Nitrophenyl)-3-(1-oxo-1,3-dihydroisobenzofuran-5-yl)thiazo-
lidin-4-one (3n). IR (KBr): 1714 cm1 n(CQO): 1H NMR (400 MHz,
DMSO d6 d in ppm) d 8.223–8.167 (m, 1H, Ar-H), 7.743–7.722
(m, 2H, Ar-H), 7.691–7.71 (m, 1H, Ar-H), 7.445–7.403 (m, 3H, Ar-H),
6.576 (s, 1H, S–CH–), 5.188 (s, 2H, –COCH2–), 3.921–9.917
(d, J = 1.6 Hz, 1H, –CH2–), 3.86–3.865 (d, J = 1.6 Hz, 1H, –CH2–);
13C NMR (100 MHz, CDCl3 d in ppm) d 171.59, 169.23, 147.28,
146.81, 145.29, 144.88, 131.24, 129.86, 124.20, 122.23, 121.12,
120.01, 73.31, 69.24, 34.18; ESI-MS m/z 357 [M + H]+; anal. calcd
for C17H12N2O5S: C, 57.30; H, 3.39; N, 7.86: found: C, 57.19; H,
3.30; N, 7.79%.
2-(4-Bromophenyl)-3-(1-oxo-1,3-dihydroisobenzofuran-5-yl)thiazo-
lidin-4-one (3o). IR (KBr): 1723 cm1 n(CQO):
1H NMR (400 MHz,
DMSO d6 d in ppm) d 8.120–8.094 (d, 1H, Ar-H), 7.835–7.819 (d, 1H,
Ar-H), 7.508 (s, 1H, Ar-H), 7.412–7.389 (m, 2H, Ar-H), 7.059–7.037(m,
2H, Ar-H), 6.403 (s, 1H, S–CH–), 5.604 (s, 2H, –COCH2–), 4.034–4.031
(d, J = 1.2 Hz, 1H, –CH2–), 3.892–3.889 (d, J = 1.2 Hz, 1H, –CH2–);
13C
NMR (100 MHz, CDCl3 d in ppm) d 171.61, 169.61, 147.35, 146.41,
138.68, 132.21, 131.83, 130.01, 122.24, 121.73, 120.88, 119.74, 73.16,
33.89; ESI-MS m/z 391 [M + H]+; anal. calcd for C17H12NO3BrS: C,
52.32; H, 3.10; N, 3.59: found: C, 52.26; H, 2.91; N, 3.48%.
3.5 Anti-bacterial studies
The anti-bacterial assay was performed using the serial dilution
method and agar diﬀusion method, at various diﬀerent con-
centrations of the new compounds.31 All the synthesized small
molecules were screened for their in vitro anti-bacterial activity
against the Gram-negative bacteria, S. typhi (MTCC 733) and K.
pneumoniae (MTCC 661), by the agar diﬀusion method at
diﬀerent concentrations. The stock cultures of bacteria were
revived by inoculating them in broth media and were grown at
37 1C for 18 h. Agar plates of the above media were prepared
and each plate was inoculated with bacterial strains. Wells were
made in the plates using a cork borer; diﬀerent concentrations
of the compounds were added and the diameters of the
inhibition zones were noted. MIC values were calculated using
the serial dilution method.
3.6 Cheminformatics analysis
In silico target prediction. Given the ever-increasing amount
of bioactivity data available, we attempted to rationalize the
mode of action of the experimentally active compounds using
in silico approaches, which is currently the topic of many
chemogenomics studies.32 In order to achieve this, we applied
the Parzen–Rosenblatt Window classifier (with the smoothing
parameter set to 0.9) to predict potential targets for the com-
pounds that were experimentally tested.23 This classifier was
trained on a large dataset comprising approximately 190 000
bioactive compounds covering 477 human protein targets. The
normalized target likelihood was calculated for each predicted
target by comparing the predicted targets in the dataset used
in this study to target predictions of a background dataset
comprising 3000 compounds in total from PubChem,33 GDB1334
and ChEMBL,35 with 1000 compounds randomly selected from
each database. All targets with a probability of 0.05 or higher
were considered as predicted in both cases. For each predicted
target, the normalized likelihood was determined by dividing the
relative frequency of the predicted target for the compound by
the relative frequency of the prediction for the same target in the
background dataset:
Normalized likelihoodtarget n ¼ fn; dataset
fn; background
Subsequently, a DELTA-BLAST protein domain similarity
search36 was performed on the predicted human protein targets
using their respective Swiss-Prot37 identifiers in order to extra-
polate from these to protein targets in S. typhi. DELTA-BLAST is
a protein sequence alignment algorithm that is aimed at
finding homologous proteins across species, based on the
similarity of their protein domains. The concept of assessing
proteins based on the similarity of their domains has been
previously explored to predict homologous targets38 and has
also been proven suitable for the prediction of novel targets for
M. tuberculosis.39 In our case, the DELTA-BLAST search was
limited to S. typhi (taxid: 90371), and the UniProtKB/Swiss-
Prot database37 was chosen as the search database due to the
high quality of its manually curated proteins. All search
parameters were set to respective default values (i.e., the
expected threshold was set to 0.01, word size was set to
3, and the maximum number of matches in a query range
set to 0), and standard scoring parameters were used, namely
the BLOSUM62 position-specific scoring matrix. The existence
of a gap was assigned a score cost of 11, whereas gap extension
costs were set at 1. Compositional adjustments were set to
composition-based statistics and the DELTA-BLAST threshold
was set at 0.05.
Comparison of bioactivity of compounds similar to com-
pound 3b. Bioactivity data for compounds with a similarity of
70% or higher to compound 3b, based on the accelrys direct
similarity measure employed by ChEMBL,40 were retrieved
from ChEMBL.35 Bioactivity data for only those compounds
with an AC50, EC50, IC50 or potency value of 10 mM or better and
a ChEMBL confidence score of 8 or higher were considered.
Subsequently, the set of targets (including duplicates) retrieved
were categorized in terms of the PANTHER26 biological pro-
cesses in which they are involved.
3.7 Molecular docking
Molecular modelling was performed in InsightII, Discovery
Studio (DS; version 2.5). The structure and mechanism of
hexameric FtsK, a double-stranded DNA (with the water mole-
cules removed), was adopted for our docking studies. The
generated ligand conformations were energy-minimized with
the CHARMM force field, using the steepest descent until
convergence. During the final step of docking using the Ligand-
Fit program (version 2.5), all the minimized conformations
were compared and redundant conformations were discarded.
Each docked pose was evaluated for its fitness using multiple
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scoring functions (LigScore1, LigScore2, -PLP1, -PLP2, Jain,
-PMF, Ludi 1, Ludi 2, Ludi 3, -PMF04, DOCK SCORE). Subsequently,
the multiple scores obtained from the calculations of LigandFit were
prioritized for each docked pose. Among the docked poses of active
compounds 3(b–o) with the hydrophobic sites of the FtsK motor
domain, those with the highest consensus scores were selected as
the favourable conformations and their complex structures were
prepared.
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